SUBSCRIBE TO OUR FREE NEWSLETTER
Daily news & progressive opinion—funded by the people, not the corporations—delivered straight to your inbox.
5
#000000
#FFFFFF
5
#000000
#FFFFFF
Demonstrators demand lower prescription drug costs in front of the New York Stock Exchange on November 14, 2019. (Photo: Erik McGregor/LightRocket via Getty Images)
Patient Groups Push Congress to Combat Big Pharma Greed in Spending Bill
"As Congress works toward finalizing an end-of-year budget package, we urge the chambers to include bipartisan legislation to address abuse of the Food and Drug Administration's citizen petition process in order to reduce drug prices and save the government hundreds of millions of dollars."
Dec 05, 2022
A coalition of patient advocacy groups on Monday urged members of Congress to include bipartisan legislation in the year-end budget package that proponents say will lower prescription drug prices--in part by reforming a citizens' petition process often abused by pharmaceutical companies to delay approval of cheaper generic medications.
"Passing the bipartisan citizen petition bill would be a win-win for Congress."
"As Congress works toward finalizing an end-of-year budget package, we urge the chambers to include bipartisan legislation to address abuse of the Food and Drug Administration's (FDA) citizen petition process in order to reduce drug prices and save the government hundreds of millions of dollars by speeding generics to market to increase competition," the eight groups, led by Patients for Affordable Drugs NOW (P4ADNow), said in a letter to congressional leaders.
The letter asserts that S. 562, the Ensuring Timely Access to Generics Act, "strengthens the FDA's ability to reject citizen petitions if it believes the primary purpose of the petition is to delay approval of a generic competitor."
The bill's proponents say the proposed legislation will more effectively identify "sham" citizen petitions filed as a means of delaying FDA approval of generic drugs and biosimilars.
"Passing the bipartisan citizen petition bill would be a win-win for Congress--it boosts competition by decreasing barriers for cheaper generic drugs to come to market, driving down prices for patients, and saving the government hundreds of millions of dollars," P4ADNow founder David Mitchell said in a statement.
The P4ADNow letter continued:
Both the Trump and Biden administrations have identified submission of sham citizen petitions as a threat to timely approval of generics and competition. In 2018, Former FDA Commissioner Scott Gottlieb noted that manipulation of the process "can add to resource burdens on the generic drug review process and the FDA's regulatory decision making" and decrease the speed of the approval process. In its 2021 drug pricing competition plan, the Biden administration also said that legislative changes were needed to "make it harder for brand manufacturers to abuse the regulatory process to prevent the introduction of biosimilar and generic products" such as through manipulation of the citizen petition process.
A 2016 analysis by Michael Carrier and Carl Minniti published in the American University Law Review revealed that brand-name drug-makers filed 92% of all FDA citizen petitions between 2011 and 2015, with the agency rejecting 90% of them.
Carrier and Minniti concluded that "citizen petitions represent a hidden tool in [Big Pharma's] toolkit of entry-delaying activity, all to the detriment of consumers forced to pay high drug prices. And in defiance of Congress' attempt to limit abuse, citizen petitions play an increasingly important role in delaying generic competition."
An Urgent Message From Our Co-Founder
Dear Common Dreams reader, It’s been nearly 30 years since I co-founded Common Dreams with my late wife, Lina Newhouser. We had the radical notion that journalism should serve the public good, not corporate profits. It was clear to us from the outset what it would take to build such a project. No paid advertisements. No corporate sponsors. No millionaire publisher telling us what to think or do. Many people said we wouldn't last a year, but we proved those doubters wrong. Together with a tremendous team of journalists and dedicated staff, we built an independent media outlet free from the constraints of profits and corporate control. Our mission has always been simple: To inform. To inspire. To ignite change for the common good. Building Common Dreams was not easy. Our survival was never guaranteed. When you take on the most powerful forces—Wall Street greed, fossil fuel industry destruction, Big Tech lobbyists, and uber-rich oligarchs who have spent billions upon billions rigging the economy and democracy in their favor—the only bulwark you have is supporters who believe in your work. But here’s the urgent message from me today. It's never been this bad out there. And it's never been this hard to keep us going. At the very moment Common Dreams is most needed, the threats we face are intensifying. We need your support now more than ever. We don't accept corporate advertising and never will. We don't have a paywall because we don't think people should be blocked from critical news based on their ability to pay. Everything we do is funded by the donations of readers like you. When everyone does the little they can afford, we are strong. But if that support retreats or dries up, so do we. Will you donate now to make sure Common Dreams not only survives but thrives? —Craig Brown, Co-founder |
Our work is licensed under Creative Commons (CC BY-NC-ND 3.0). Feel free to republish and share widely.
A coalition of patient advocacy groups on Monday urged members of Congress to include bipartisan legislation in the year-end budget package that proponents say will lower prescription drug prices--in part by reforming a citizens' petition process often abused by pharmaceutical companies to delay approval of cheaper generic medications.
"Passing the bipartisan citizen petition bill would be a win-win for Congress."
"As Congress works toward finalizing an end-of-year budget package, we urge the chambers to include bipartisan legislation to address abuse of the Food and Drug Administration's (FDA) citizen petition process in order to reduce drug prices and save the government hundreds of millions of dollars by speeding generics to market to increase competition," the eight groups, led by Patients for Affordable Drugs NOW (P4ADNow), said in a letter to congressional leaders.
The letter asserts that S. 562, the Ensuring Timely Access to Generics Act, "strengthens the FDA's ability to reject citizen petitions if it believes the primary purpose of the petition is to delay approval of a generic competitor."
The bill's proponents say the proposed legislation will more effectively identify "sham" citizen petitions filed as a means of delaying FDA approval of generic drugs and biosimilars.
"Passing the bipartisan citizen petition bill would be a win-win for Congress--it boosts competition by decreasing barriers for cheaper generic drugs to come to market, driving down prices for patients, and saving the government hundreds of millions of dollars," P4ADNow founder David Mitchell said in a statement.
The P4ADNow letter continued:
Both the Trump and Biden administrations have identified submission of sham citizen petitions as a threat to timely approval of generics and competition. In 2018, Former FDA Commissioner Scott Gottlieb noted that manipulation of the process "can add to resource burdens on the generic drug review process and the FDA's regulatory decision making" and decrease the speed of the approval process. In its 2021 drug pricing competition plan, the Biden administration also said that legislative changes were needed to "make it harder for brand manufacturers to abuse the regulatory process to prevent the introduction of biosimilar and generic products" such as through manipulation of the citizen petition process.
A 2016 analysis by Michael Carrier and Carl Minniti published in the American University Law Review revealed that brand-name drug-makers filed 92% of all FDA citizen petitions between 2011 and 2015, with the agency rejecting 90% of them.
Carrier and Minniti concluded that "citizen petitions represent a hidden tool in [Big Pharma's] toolkit of entry-delaying activity, all to the detriment of consumers forced to pay high drug prices. And in defiance of Congress' attempt to limit abuse, citizen petitions play an increasingly important role in delaying generic competition."
A coalition of patient advocacy groups on Monday urged members of Congress to include bipartisan legislation in the year-end budget package that proponents say will lower prescription drug prices--in part by reforming a citizens' petition process often abused by pharmaceutical companies to delay approval of cheaper generic medications.
"Passing the bipartisan citizen petition bill would be a win-win for Congress."
"As Congress works toward finalizing an end-of-year budget package, we urge the chambers to include bipartisan legislation to address abuse of the Food and Drug Administration's (FDA) citizen petition process in order to reduce drug prices and save the government hundreds of millions of dollars by speeding generics to market to increase competition," the eight groups, led by Patients for Affordable Drugs NOW (P4ADNow), said in a letter to congressional leaders.
The letter asserts that S. 562, the Ensuring Timely Access to Generics Act, "strengthens the FDA's ability to reject citizen petitions if it believes the primary purpose of the petition is to delay approval of a generic competitor."
The bill's proponents say the proposed legislation will more effectively identify "sham" citizen petitions filed as a means of delaying FDA approval of generic drugs and biosimilars.
"Passing the bipartisan citizen petition bill would be a win-win for Congress--it boosts competition by decreasing barriers for cheaper generic drugs to come to market, driving down prices for patients, and saving the government hundreds of millions of dollars," P4ADNow founder David Mitchell said in a statement.
The P4ADNow letter continued:
Both the Trump and Biden administrations have identified submission of sham citizen petitions as a threat to timely approval of generics and competition. In 2018, Former FDA Commissioner Scott Gottlieb noted that manipulation of the process "can add to resource burdens on the generic drug review process and the FDA's regulatory decision making" and decrease the speed of the approval process. In its 2021 drug pricing competition plan, the Biden administration also said that legislative changes were needed to "make it harder for brand manufacturers to abuse the regulatory process to prevent the introduction of biosimilar and generic products" such as through manipulation of the citizen petition process.
A 2016 analysis by Michael Carrier and Carl Minniti published in the American University Law Review revealed that brand-name drug-makers filed 92% of all FDA citizen petitions between 2011 and 2015, with the agency rejecting 90% of them.
Carrier and Minniti concluded that "citizen petitions represent a hidden tool in [Big Pharma's] toolkit of entry-delaying activity, all to the detriment of consumers forced to pay high drug prices. And in defiance of Congress' attempt to limit abuse, citizen petitions play an increasingly important role in delaying generic competition."
We've had enough. The 1% own and operate the corporate media. They are doing everything they can to defend the status quo, squash dissent and protect the wealthy and the powerful. The Common Dreams media model is different. We cover the news that matters to the 99%. Our mission? To inform. To inspire. To ignite change for the common good. How? Nonprofit. Independent. Reader-supported. Free to read. Free to republish. Free to share. With no advertising. No paywalls. No selling of your data. Thousands of small donations fund our newsroom and allow us to continue publishing. Can you chip in? We can't do it without you. Thank you.